Embecta 2026 guidance cut sharply on U.S. pen needle collapse

 

Embecta Q2 2026 EPS $0.27 (-61% YoY), revenue $221.8M (-14% YoY) miss as 2026 guidance cut sharply on U.S. pen needle collapse

• Q2 revenue fell 17% constant currency, with U.S. down nearly 30%, missing expectations.
• Full-year revenue, margin and EPS guidance cut sharply; free cash flow outlook nearly halved.
• U.S. pen needle share loss at major retailer and market softness drive ~70% downgrade.
• Management sees emerging structural headwinds from GLP-1 adoption and insurance changes, uncertainty remains high.
• Owen Mumford acquisition proceeds; adds auto-injector platform and diversifies beyond insulin devices.
• Acquisition and lower U.S. profitability raise tax rate to 28% and pressure EPS.
• Cost structure and footprint under review; company still targeting $150M 2026 debt repayment.
• Dividend slashed from $0.15 to $0.01 to fund $100M buyback, enhance flexibility.
• International performance largely on plan; China stabilizing after last year’s significant declines.
• GLP-1 B2B pipeline expanding, with early launches in India and retail packs globally.
• Main concern: Structural decline in insulin pen/needle demand and embecta’s ability to stabilize U.S. share.
• Weak quarter, driven by U.S. pen needle share loss and broad reductions to 2026 guidance.

https://finviz.com/quote?t=EMBC&p=d